Takeaway
- Real-world findings show that direct oral anticoagulants (DOACs) are comparably effective to warfarin in reducing the risk for recurrent thrombosis and increasing the likelihood of recanalization in patients with cerebral venous thrombosis (CVT).
- Additionally, DOAC users have a significantly lower risk for major bleeding compared with warfarin users.
Why this matters...
